Has APOL1 kidney disease treatment been hiding in plain sight?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39577983.
- Also identified by DOI 10.1016/j.kint.2024.09.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Two coding variants of APOL1 account for much of the excess risk of focal segmental glomerulosclerosis in people of recent West African ancestry. There is an unmet need of treatment for apolipoprotein L1 kidney disease. In this issue, Sula Karreci et al. reported that lisinopril reduced proteinuria and glomerulosclerosis in a mouse model of apolipoprotein L1-induced focal segmental glomerulosclerosis, in a genotype-specific manner. By contrast, hydralazine and dapagliflozin had no effect. This study highlights the potential therapeutic utility of angiotensin-converting enzyme inhibitor in apolipoprotein L1 kidney disease.
Medical subject headings
- Apolipoprotein L1
- Glomerulosclerosis, Focal Segmental
- Angiotensin-Converting Enzyme Inhibitors